Compound’s direct lending underwriting model of Xponential Fitness starts from a gap: reported EBITDA of $15.6 million for the twelve months to September 30, 2026 against management’s Adjusted EBITDA of $89.5 million. Addbacks are 82.6% of the adjusted figure. After the lender case’s haircuts, chiefly half credit for litigation costs that recur every year and a quarter of the restructuring charges, lender EBITDA is $67.3 million, and the $531.1 million of debt is 7.9x that figure against 5.9x on management’s.
Carried forward, all three cases test above the 5.00x leverage covenant when it steps down on March 31, 2028: the management case at 5.06x, the lender case at 6.10x, and the downside case, sized to the company’s FY2020, breaches in June 2027. The lender case runs out of liquidity in the third quarter of 2028. These are the model’s results under its haircuts and its projections, and the years after 2026 are Compound’s own assumptions, because the company gives no multi-year guidance. They are not a forecast of a default and not a view on the company, its lenders or its securities. One more caveat sits at the start: the request asked for a sponsor-backed borrower, and Xponential is not sponsor-controlled. Compound said so and used it as a stand-in.
You are underwriting a senior secured loan to a middle-market company. You need the terms from the documents, an EBITDA you would lend against, cases that show where the covenant and the cash run out, and a yield that reflects the OID. We asked Compound to build that model on a real borrower from public filings. It ran on November 19, 2026 and returned one Excel workbook of eight sheets and a short written answer.
What the workbook shows:
- The borrower and the loan. A $525 million first lien term loan and a $25 million revolver closed on December 8, 2025, with HPS Investment Partners as agent, priced at SOFR + 6.75% with a 1.00% floor and 3.4% OID. The only financial covenant is maximum total net leverage.
- The addbacks. $73.9 million of addbacks on $15.6 million of reported EBITDA in the last twelve months, led by $27.1 million of litigation and a $27.3 million loss on debt extinguishment.
- The lender view. Fifteen addbacks, each with a credit percentage and a reason. The haircuts take $22.2 million, 24.8%, off management’s figure and add 1.96 turns of leverage.
- Three cases to the December 2030 maturity. Management from guidance, lender with lower growth and margins, and a downside that repeats FY2020.
- Covenant headroom by quarter. 18.7% at September 30, 2026, then negative in every case at the March 2028 step-down.
- The pricing. An all-in yield of 13.28% to a three-year take-out and 12.84% to maturity, beside the cost and fair value at which two BDCs carry the loan.
The loan terms come from the 8-K of December 8, 2025 and the credit agreement filed as its Exhibit 10.1, the historicals and guidance from Xponential’s 10-Ks, 10-Qs and earnings releases, and the BDC holdings from the September 30, 2026 schedules of investments of Fortress Private Lending Fund and HPS Corporate Capital Solutions Fund, all on SEC EDGAR. Settlement payments and cost review commentary come from the Q3 2026 earnings call, and floating-rate interest from the SOFR forward curve of November 19, 2026. Every other input is marked as an analyst assumption with a reason.
“I am underwriting a senior secured loan to a sponsor-backed company and want a direct lending underwriting model built on a real borrower. From SEC EDGAR, pick one U.S. public company with under $250 million of EBITDA that in the last 24 months disclosed a senior secured term loan or unitranche from a private credit lender (a BDC or direct lending fund), with the credit agreement filed as an exhibit. Take the pricing, amortization, maturity, fees and financial covenant levels from the credit agreement or the 8-K. Build historicals for the last three fiscal years and the latest twelve months from the 10-K and 10-Q, showing reported EBITDA, each addback management takes, and Adjusted EBITDA. Build three cases over five years: a management case from company guidance or the latest earnings call; a lender case that haircuts the addbacks I would not give full credit for and lowers growth and margins, with a note on each haircut; and a downside case sized to a recession like the company's own worst year. For each case show total and senior net leverage, interest coverage, fixed charge coverage, free cash flow after debt service, liquidity from cash plus undrawn revolver, and headroom to each financial covenant by quarter for the first two years. Price the loan off the SOFR forward curve plus the contractual spread and floor, with the OID and fees, and show the all-in yield to a three-year take-out and to maturity. If a public BDC lists this loan in its schedule of investments, show its cost, fair value and spread next to the model. Flag lender-case leverage above 6.0x, fixed charge coverage below 1.2x, covenant headroom below 20% in any quarter, and liquidity below six months of fixed charges in the downside case. Use the stored public data wherever it has the figure, and web search only for what it lacks. Put every input on an Assumptions sheet with one column that says where it came from: a cited source, or "analyst assumption" for a figure I would set myself, with the reason for the value you chose. Every output must be a live formula that traces back to the Assumptions sheet. Add a Sources sheet listing each data source, what it gave and its date. Deliver one Excel workbook and a short summary of the result, the flags, and what I would need from the sponsor and management to firm it up. Cite every sourced figure.”
That is the request as we sent it, without its closing line, which asks that no name or email be put in the workbook.
Choosing the borrower: Xponential Fitness and its HPS term loan
Compound picked Xponential Fitness, a franchisor with $89.5 million of last-twelve-month Adjusted EBITDA, whose December 2025 refinancing is a private credit term loan with the credit agreement on file. It is not sponsor-controlled, and the answer says so: “Xponential is not sponsor-controlled, so it stands in for your borrower.”
| B | D | |
|---|---|---|
| 5 | FACILITY | |
| 6 | Borrower | Xponential Fitness LLC (subsidiary of Xponential Fitness, Inc., NYSE: XPOF) |
| 7 | Agent and lenders | HPS Investment Partners LLC, as agent; private credit lender group |
| 8 | Facilities | $525M first lien term loan and $25M revolver |
| 9 | Closing and maturity | Dec 8, 2025 to Dec 8, 2030 |
| 10 | Pricing | Term SOFR + 6.75% (grid down to 5.75%), 1.00% floor, OID 3.4%, issue price 96.4% |
| 11 | Amortization | 1.0% a year in 2026, 3.0% in 2027, 5.0% from 2028; 50% ECF sweep |
| 12 | Financial covenant | Max Total Net Leverage 7.00x through 2026, 6.25x in 2027, 5.00x from Q1 2028 |
| 13 | Call protection | Premium of 3% / 2% / 1% in years 1-3 |
The credit agreement sets more than the headline terms, and the Assumptions sheet carries each clause with its section. The margin steps down a grid on first lien net leverage, from 6.75% at 4.25x and above to 5.75% below 3.50x. The model holds 6.75% throughout because leverage stays above 4.25x in every case. The unused revolver fee is 0.50%. Unrestricted cash netted in the leverage test is capped at $50 million. The excess cash flow sweep is 50%, stepping to 25% at 3.5x first lien net leverage and to nothing at 3.0x, and the prepayment premium runs 3%, 2% and 1% over the first three years.
The OID comes from the Q3 2026 10-Q, which also gives net proceeds of $506.2 million. The gap between the two implies 0.19% of other upfront fees, so lenders funded at 96.41% of par. The revolver was first drawn for $10.0 million on April 7, 2026, and term loan principal was $521.1 million at September 30, 2026. Total debt of $531.1 million is the starting point for every ratio below. The credit agreement analysis page covers that clause-by-clause review.
Reported EBITDA to Adjusted EBITDA: addbacks of 82.6%
For the twelve months to September 30, 2026, $73.9 million of addbacks turn $15.6 million of reported EBITDA into $89.5 million of Adjusted EBITDA. In FY2024 the addbacks were larger than Adjusted EBITDA itself.
| B | D | E | F | G | |
|---|---|---|---|---|---|
| 5 | Period | 12/31/2023 | 12/31/2024 | 12/31/2025 | 9/30/2026 |
| 7 | Revenue ($000) | 317,937 | 320,346 | 314,879 | 271,907 |
| 9 | Net income (loss) | (6,443) | (98,696) | (53,671) | (46,355) |
| 10 | (+) Interest expense, net | 37,122 | 44,426 | 45,977 | 53,759 |
| 11 | (+) Income taxes (benefit) | 1,034 | (342) | 1,322 | 453 |
| 12 | (+) Depreciation and amortization | 16,883 | 17,713 | 12,027 | 7,765 |
| 13 | Reported EBITDA ($000) | 48,596 | (36,899) | 5,655 | 15,622 |
| 17 | (+) Equity-based compensation | 17,997 | 15,465 | 12,908 | 10,287 |
| 19 | (+) Acquisition and transaction expenses (income) | (18,464) | 8,886 | (6,948) | (5,057) |
| 20 | (+) Litigation expenses | 6,839 | 32,575 | 30,097 | 27,125 |
| 21 | (+) Financial transaction fees and related expenses | 9,038 | 620 | 408 | 5,301 |
| 23 | (+) Impairment of goodwill and other noncurrent assets | 16,750 | 62,551 | 32,718 | 307 |
| 24 | (+) Loss and expenses due to brand divestitures and wind down | - | 1,820 | 5,570 | 6,773 |
| 30 | (+) Loss on debt extinguishment | - | - | 27,327 | 27,327 |
| 31 | (+) Restructuring and related charges | 15,700 | 26,287 | 3,979 | 2,123 |
| 32 | Total management addbacks | 51,725 | 153,116 | 106,123 | 73,909 |
| 33 | Adjusted EBITDA, management ($000) | 100,321 | 116,217 | 111,778 | 89,531 |
| 36 | Addbacks as % of Adjusted EBITDA | 51.6% | 131.8% | 94.9% | 82.6% |
The bridge ties to the company’s reported figures in every period. Two lines dominate the last twelve months. Litigation expenses are $27.1 million, and the loss on debt extinguishment from the December 2025 refinancing is $27.3 million. Equity-based compensation adds $10.3 million and brand divestitures and wind-down $6.8 million, while acquisition and transaction income takes $5.1 million out, because it is mostly fair-value income on contingent consideration.
Management addbacks as a share of Adjusted EBITDA
Total addbacks over management Adjusted EBITDA. LTM is the twelve months to September 30, 2026
Compound's Historicals tab, row 36: Xponential Fitness earnings releases and Form 10-K and 10-Q filings, FY2023 as corrected.
The pattern matters more than any one year. Litigation is added back in every period: $6.8 million in FY2023, $32.6 million in FY2024 and $30.1 million in FY2025. Restructuring charges are added back every year too, at $15.7 million, $26.3 million and $4.0 million. FY2023 was restated, and the sheet notes that Adjusted EBITDA was cut from $105.3 million to $100.3 million. Revenue in the last twelve months is $271.9 million, 13.6% below FY2025, partly from divestitures. Free cash flow after interest over the same twelve months is negative $13.7 million, which the sheet ties to litigation settlement payments and the higher interest bill after the refinancing. For how a credit team rebuilds an addback schedule, see adjusted EBITDA.
The lender case haircuts: costs that keep coming back
Compound gives full credit to the non-cash addbacks and cuts the cash costs that recur: half credit for litigation, financial transaction fees, brand wind-down and transformation costs, a quarter for restructuring, and none for executive transitions or payroll taxes on equity awards. That takes $22.2 million off last-twelve-month Adjusted EBITDA.
| B | E | S | |
|---|---|---|---|
| 160 | Management addback | Lender | Haircut note (analyst assumption) |
| 161 | Equity-based compensation | 100% | Full credit: non-cash, permitted by the Credit Agreement definition; RSU tax payments sit in other cash items |
| 162 | Employer payroll taxes on equity-based compensation | 0% | No credit: cash payroll tax that recurs with every vesting |
| 163 | Acquisition and transaction expenses (income) | 100% | Full credit: mostly fair-value changes in contingent consideration, non-cash; it deducts gains as well as adding back losses |
| 164 | Litigation expenses | 50% | 50% credit: legal costs appear in every period FY2023-9M 2026 ($6.8M, $32.6M, $30.1M, $5.4M), so half is treated as run-rate; settlement-driven spikes credited at half pending a matter-by-matter schedule |
| 165 | Financial transaction fees and related expenses | 50% | 50% credit: strategic and financing transaction fees recurred in FY2023 and 2026; cash cost |
| 166 | TRA remeasurement | 100% | Full credit: non-cash remeasurement of the tax receivable agreement |
| 167 | Impairment of goodwill and other noncurrent assets | 100% | Full credit: non-cash |
| 168 | Loss and expenses due to brand divestitures and wind down | 50% | 50% credit: losses of exited brands are removable, but wind-down costs have recurred 2024-2026 |
| 169 | Executive transition costs | 0% | No credit: CEO, CFO and COO transitions in 2024-2026 make leadership turnover recurring |
| 170 | Non-recurring rebranding expenses | 100% | Full credit: single occurrence in FY2024 |
| 171 | Transformation initiative costs | 50% | 50% credit: consulting spend in FY2024-FY2025 and a new cost review in 2027 |
| 172 | Contract settlement costs | 100% | Full credit: single settlement in FY2024 |
| 173 | Other income (royalties from divested brands) | 100% | Full credit: removes royalty income from divested brands (a deduction) |
| 174 | Loss on debt extinguishment | 100% | Full credit: financing cost of the Dec 2025 refinancing, not operating |
| 175 | Restructuring and related charges | 25% | 25% credit: restructuring charges recur every year FY2023-9M 2026 |
Each note gives the reason in a line. Litigation gets half credit because “legal costs appear in every period”, so half is treated as run-rate, and settlement spikes are “credited at half pending a matter-by-matter schedule”. Restructuring gets a quarter because the charges “recur every year FY2023-9M 2026”. Executive transitions get nothing because the CEO, CFO and COO transitions of 2024 to 2026 “make leadership turnover recurring”. The lender keeps full credit for equity-based compensation, impairment, the tax receivable agreement remeasurement and the loss on debt extinguishment, all non-cash or financing items.
From management Adjusted EBITDA to lender EBITDA, last twelve months
Twelve months to September 30, 2026. Each step is the part of an addback the lender case does not credit
Compound's Historicals tab, the management and lender addback blocks, LTM column. Each step is the management addback less the amount the lender credits (our arithmetic); the steps sum to the $22.2 million haircut on row 57.
Litigation is the haircut that decides the number: $13.6 million of the $22.2 million (our arithmetic). It is also the judgment a credit committee will argue about. The last-twelve-month figure includes a $21.8 million litigation addback in the fourth quarter of 2025, while the nine months of 2026 carry only $5.4 million.
| B | D | E | F | G | |
|---|---|---|---|---|---|
| 54 | Total addbacks credited by lender | 31,340 | 114,124 | 84,367 | 51,689 |
| 55 | Lender-adjusted EBITDA ($000) | 79,936 | 77,225 | 90,022 | 67,311 |
| 56 | Lender-adjusted EBITDA margin | 25.1% | 24.1% | 28.6% | 24.8% |
| 57 | Haircut to management Adjusted EBITDA | (20,386) | (38,992) | (21,756) | (22,220) |
| 58 | Haircut as % of management Adjusted EBITDA | (20.3%) | (33.6%) | (19.5%) | (24.8%) |
| 60 | Memo: total debt at Sep 30, 2026 (term loan + revolver) | 531,063 | |||
| 61 | Memo: total leverage on management Adjusted EBITDA (x) | 5.93x | |||
| 62 | Memo: total leverage on lender-adjusted EBITDA (x) | 7.89x | |||
| 63 | Memo: leverage added by the haircuts (turns) | 1.96x |
The haircut was 20.3%, 33.6% and 19.5% of Adjusted EBITDA in FY2023 to FY2025, so 24.8% today is no outlier. On the $531.1 million of debt at September 30, 2026, leverage is 5.93x management EBITDA and 7.89x lender EBITDA, 1.96 turns apart.
The haircuts feed the lender’s own statistics: total and senior leverage, interest coverage and fixed charge coverage. They do not feed the covenant test. Compound takes the company’s Adjusted EBITDA as covenant EBITDA, an assumption the answer names first among those “that change the answer”. The credit agreement permits these addbacks and run-rate items up to 25% of Consolidated EBITDA, so the covenant figure the borrower reports could be higher than the model’s.
Three cases over five years
The management case starts from the 2026 guidance midpoint of $92.5 million of Adjusted EBITDA, the lender case from the low end of $91.0 million with revenue down 3% in 2027, and the downside repeats FY2020 in 2027: revenue down 17.5% and Adjusted EBITDA down 40.5%.
The guidance was cut during the year, from $100 million to $110 million in February 2026 to $91 million to $94 million on November 5, 2026, with North America same store sales down 7.5% in the third quarter. The drivers after 2026 are Compound’s assumptions, each with a reason on the Assumptions sheet.
| Driver (Assumptions, Section E) | Management | Lender | Downside |
|---|---|---|---|
| FY2026E revenue | $255.0 million, guidance midpoint | $250.0 million, guidance low end | $250.0 million |
| FY2026E Adjusted EBITDA | $92.5 million | $91.0 million | $91.0 million |
| Revenue growth, FY2027E to FY2030E | 2%, 4%, 5%, 5% | -3%, 0%, 2%, 2% | -17.45%, 8%, 3%, 2% |
| Adjusted EBITDA margin, FY2027E to FY2030E | 36.5% rising to 38% | 35% then 34.5% | 26.25% rising to 33% |
| Addback credit | Full | Haircut as above | Haircut as above |
The downside is the request’s recession, sized to the company’s own worst year. FY2020, the year of studio closures, took revenue from $129.1 million to $106.6 million and Adjusted EBITDA from $16.5 million to $9.8 million, and the model applies both changes to FY2027.
| B | D | E | F | |
|---|---|---|---|---|
| 30 | Metric | Management | Lender | Downside |
| 31 | FY2027E revenue ($000) | 260,100 | 242,500 | 206,366 |
| 32 | FY2027E Adjusted EBITDA, company definition ($000) | 94,937 | 84,875 | 54,172 |
| 33 | FY2027E credited EBITDA, case basis ($000) | 94,937 | 76,850 | 45,397 |
| 34 | Peak total leverage, credited EBITDA, Q4 2026-Q3 2028 (x) | 5.67x | 6.88x | 11.65x |
| 35 | Peak senior secured net leverage, Q4 2026-Q3 2028 (x) | 5.51x | 6.71x | 12.11x |
| 36 | Minimum interest coverage, Q4 2026-Q3 2028 (x) | 1.60x | 1.26x | 0.74x |
| 37 | Minimum fixed charge coverage, Q4 2026-Q3 2028 (x) | 1.14x | 0.87x | 0.55x |
| 38 | Minimum covenant headroom, Q4 2026-Q3 2028 | (1.2%) | (22.4%) | (82.2%) |
| 39 | First covenant breach (quarter end) | 3/31/2028 | 3/31/2028 | 6/30/2027 |
| 40 | Cumulative FCF after debt service, FY2027E-FY2030E ($000) | 40,381 | (80,096) | (150,315) |
| 41 | Minimum liquidity, Q4 2026-Q3 2028 ($000) | 35,492 | (6,129) | (53,128) |
| 42 | Minimum liquidity in months of fixed charges, Q4 2026-Q3 2028 | 5.3 | (0.9) | (7.6) |
| 43 | Peak revolver drawn, Q4 2026-Q4 2030 ($000) | 4,508 | 25,000 | 25,000 |
| 44 | Lowest unrestricted cash, Q4 2026-Q4 2030 ($000; negative = funding gap) | 15,000 | (46,577) | (116,643) |
| 45 | Total leverage, credited EBITDA, FY2030E (x) | 3.74x | 5.51x | 6.26x |
| 46 | Term loan outstanding at Dec 2030 maturity ($000) | 423,872 | 425,250 | 425,250 |
In FY2027 the lender case’s credited EBITDA of $76.9 million is $18.1 million below management’s $94.9 million. Lower growth and margin account for $10.1 million of that and the haircuts for $8.0 million (our arithmetic). The haircuts shrink over time, from $12.9 million in FY2026 to $5.4 million a year from FY2028, because the lender case projects litigation at a $4.0 million to $5.0 million run-rate rather than at the settlement-year levels.
In every case about $424 million of the term loan is still outstanding at the December 2030 maturity: $423.9 million in the management case, where a small excess cash flow sweep is paid in 2030, and $425.3 million in the other two.
Covenant headroom by quarter and the March 2028 step-down
At September 30, 2026, covenant net leverage is 5.69x against 7.00x, 18.7% headroom. The covenant steps to 6.25x in March 2027 and to 5.00x in March 2028, and at that second step the management case tests at 5.06x and the lender case at 6.10x. The downside breaches at 6.99x in June 2027.
Total net leverage, covenant basis, against the covenant
Quarter ends, December 2026 to September 2028. Net debt over LTM company Adjusted EBITDA, cash netted up to $50 million
Compound's Summary tab, covenant headroom block, from the quarterly Mgmt Case, Lender Case and Downside Case tabs. Covenant levels from Section 7.12 of the credit agreement.
| B | D | E | F | G | H | I | J | K | |
|---|---|---|---|---|---|---|---|---|---|
| 49 | Quarter end | 12/31/2026 | 3/31/2027 | 6/30/2027 | 9/30/2027 | 12/31/2027 | 3/31/2028 | 6/30/2028 | 9/30/2028 |
| 50 | Maximum Total Net Leverage (x) | 7.00x | 6.25x | 6.25x | 6.25x | 6.25x | 5.00x | 5.00x | 5.00x |
| 51 | Management: total net leverage, covenant basis (x) | 5.51x | 5.27x | 5.13x | 5.12x | 5.20x | 5.06x | 4.92x | 4.79x |
| 52 | Management: headroom (EBITDA cushion) | 21.4% | 15.7% | 17.9% | 18.0% | 16.9% | (1.2%) | 1.6% | 4.3% |
| 53 | Management: fixed charge coverage (x) | 1.43x | 1.40x | 1.35x | 1.27x | 1.20x | 1.17x | 1.15x | 1.14x |
| 54 | Management: liquidity ($000) | 35,492 | 35,856 | 35,876 | 35,721 | 35,644 | 35,686 | 35,957 | 36,345 |
| 55 | Lender: total net leverage, covenant basis (x) | 5.62x | 5.57x | 5.63x | 5.84x | 6.08x | 6.10x | 6.12x | 6.07x |
| 56 | Lender: headroom (EBITDA cushion) | 19.7% | 10.8% | 9.9% | 6.5% | 2.8% | (22.0%) | (22.4%) | (21.3%) |
| 57 | Lender: fixed charge coverage (x) | 1.20x | 1.17x | 1.12x | 1.03x | 0.95x | 0.92x | 0.89x | 0.87x |
| 58 | Lender: liquidity ($000) | 33,519 | 28,996 | 23,966 | 18,604 | 13,181 | 6,549 | 156 | (6,129) |
| 59 | Downside: total net leverage, covenant basis (x) | 5.62x | 6.18x | 6.99x | 8.20x | 9.77x | 9.11x | 8.52x | 8.00x |
| 60 | Downside: headroom (EBITDA cushion) | 19.8% | 1.1% | (11.9%) | (31.2%) | (56.2%) | (82.2%) | (70.5%) | (59.9%) |
| 61 | Downside: fixed charge coverage (x) | 1.20x | 1.06x | 0.90x | 0.72x | 0.55x | 0.58x | 0.61x | 0.64x |
| 62 | Downside: liquidity ($000) | 33,672 | 20,764 | 7,121 | (6,880) | (20,793) | (31,774) | (42,509) | (53,128) |
The step-down is 1.25 turns in one quarter, and the cases get there in different shape. The management case holds 16% to 18% of headroom through 2027 and misses the March 2028 test by 1.2% of EBITDA. About 1.2% more last-twelve-month EBITDA at that date would clear it (our arithmetic), and the case passes again in June 2028 at 4.92x. That miss rests on Compound’s assumed 2% revenue growth and 36.5% margin for 2027; company guidance stops at 2026.
The lender case misses by 22.0%. Its covenant test runs on company Adjusted EBITDA, so the miss comes from the operating case. Revenue falling 3% in 2027 and the margin settling near 35% take LTM Adjusted EBITDA down to $83.7 million by FY2028, and once cash runs out there is nothing left to net against debt. The downside’s headroom is 1.1% in March 2027, negative from June 2027, and reaches negative 82.2% in March 2028. For the quarterly test itself, the covenant compliance calculation page works through a certificate clause by clause.
Coverage, free cash flow and liquidity
Scheduled amortization rises from $5.3 million in 2026 to $26.3 million a year from 2028, and fixed charge coverage falls with it: to 1.14x in the management case and below 1.0x from December 2027 in the lender case. The lender case draws the revolver in full and has a funding gap from the third quarter of 2028.
| B | AD | AE | AF | AG | AH | |
|---|---|---|---|---|---|---|
| 5 | Period end | 12/31/2026 | 12/31/2027 | 12/31/2028 | 12/31/2029 | 12/31/2030 |
| 32 | Adjusted EBITDA, company definition ($000) | 91,000 | 84,875 | 83,663 | 85,336 | 87,042 |
| 34 | (-) Haircut to addbacks not credited in this case | (12,900) | (8,025) | (5,400) | (5,400) | (5,400) |
| 35 | Credited EBITDA, case basis ($000) | 78,100 | 76,850 | 78,263 | 79,936 | 81,642 |
| 44 | Cash EBITDA ($000) | 67,800 | 70,725 | 74,513 | 76,186 | 77,892 |
| 45 | (-) Change in working capital incl. deferred revenue | (29,065) | (9,000) | (8,000) | (7,000) | (7,000) |
| 48 | Operating cash flow before interest ($000) | 34,798 | 60,225 | 64,956 | 67,259 | 68,626 |
| 50 | CFADS: cash flow available for debt service ($000) | 31,350 | 55,981 | 60,712 | 62,930 | 64,210 |
| 51 | (-) Cash interest and fees | (56,619) | (60,570) | (59,839) | (56,085) | (52,937) |
| 52 | (-) Scheduled amortization | (5,250) | (15,750) | (26,250) | (26,250) | (26,250) |
| 53 | FCF after debt service ($000) | (30,519) | (20,338) | (25,377) | (19,405) | (14,976) |
| 68 | Revolver drawn, closing ($000) | 6,481 | 25,000 | 25,000 | 25,000 | 25,000 |
| 75 | Unrestricted cash ($000) | 15,000 | 13,181 | (12,196) | (31,600) | (46,577) |
| 97 | Total leverage, credited EBITDA (x) | 6.74x | 6.88x | 6.42x | 5.96x | 5.51x |
| 99 | Total net leverage, covenant basis (x) | 5.62x | 6.08x | 6.01x | 5.58x | 5.17x |
| 101 | Covenant headroom (EBITDA cushion) | 19.7% | 2.8% | (20.2%) | (11.7%) | (3.5%) |
| 108 | Fixed charge coverage (x) | 1.20x | 0.95x | 0.86x | 0.91x | 0.97x |
| 110 | Liquidity: unrestricted cash + undrawn revolver ($000) | 33,519 | 13,181 | (12,196) | (31,600) | (46,577) |
| 112 | Liquidity in months of fixed charges | 6.5 | 2.1 | (1.7) | (4.6) | (7.1) |
Three cash drains sit between Adjusted EBITDA and debt service. Cash costs inside the addbacks are still cash out: $14.2 million in the lender case in FY2027. Deferred revenue unwinds as upfront franchise fees are recognized without new cash, after falling $31.7 million in FY2025 and $7.5 million in the nine months of 2026, and the lender case assumes $9.0 million of working capital outflow in 2027. And interest on the floored SOFR plus 6.75% runs at about $60 million a year.
The result is negative free cash flow after debt service in every year of the lender case, $80.1 million in total from FY2027 to FY2030. The management case is positive by $40.4 million over the same years and the downside negative by $150.3 million. In the management case fixed charge coverage falls from 1.43x in December 2026 to 1.14x by September 2028, as the amortization step lands on interest that has not fallen.
| B | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|
| 65 | Test | Management | Lender | Downside | Threshold | First flagged | Status |
| 66 | Lender-case total leverage on credited EBITDA above threshold (x) | 0 | 12 | 17 | 6.00x | 12/31/2026 | FLAG |
| 67 | Fixed charge coverage below threshold (x) | 7 | 16 | 16 | 1.20x | 12/31/2027 | FLAG |
| 68 | Covenant headroom below threshold, any quarter | 11 | 17 | 17 | 20% | 3/31/2027 | FLAG |
| 69 | Downside liquidity below months of fixed charges | 7 | 16 | 16 | 6.0 | 3/31/2027 | FLAG |
All four of the request’s flags trip. Lender-case leverage on credited EBITDA is above 6.0x in 12 quarters from December 2026. Fixed charge coverage is below 1.2x in 7, 16 and 16 quarters across the three cases. Headroom is below 20% in 11, 17 and 17 quarters, from March 2027 in the management case. Downside liquidity falls below six months of fixed charges from March 2027 and is negative from September 2027. The management case sits below six months too, at a minimum of 5.3 months, because the model holds $15 million of unrestricted cash and the undrawn revolver is the only other source.
Pricing: all-in yield to take-out and maturity, and the BDC marks
Funded at 96.41% of par and priced off the November 19, 2026 SOFR forward curve, the loan yields 13.28% to a three-year take-out and 12.84% to maturity, about 836 and 790 basis points over average SOFR. Two BDCs carry it at fair values of 97.1% and 96.7% of par.
| B | D | |
|---|---|---|
| 5 | LOAN TERMS | |
| 6 | Face amount ($000) | 525,000 |
| 7 | Closing date | 12/8/2025 |
| 8 | Maturity date | 12/8/2030 |
| 9 | Take-out date (three-year take-out) | 12/8/2028 |
| 10 | Original issue discount | 3.40% |
| 11 | Other upfront fees | 0.19% |
| 12 | Issue price (net funded) | 96.41% |
| 13 | Margin over Term SOFR | 6.75% |
| 14 | Term SOFR floor | 1.00% |
| 15 | Prepayment premium at take-out date | 0.00% |
| 16 | Day count basis (days) | 360 |
| 18 | ALL-IN YIELD | |
| 19 | All-in yield to three-year take-out (annual effective, XIRR) | 13.28% |
| 20 | All-in yield to maturity (annual effective, XIRR) | 12.84% |
| 21 | Yield to take-out, quarterly-compounded equivalent | 12.67% |
| 22 | Yield to maturity, quarterly-compounded equivalent | 12.27% |
| 23 | Average floored Term SOFR to take-out (day-weighted) | 4.31% |
| 24 | Implied all-in spread to take-out (quarterly-compounded yield less average SOFR) | 8.36% |
| 25 | Average floored Term SOFR to maturity (day-weighted) | 4.37% |
| 26 | Implied all-in spread to maturity | 7.90% |
| 27 | Memo: OID and fees spread evenly over the take-out horizon (per year) | 1.20% |
The cash flow schedule runs quarterly on ACT/360. Past resets use the rates the filings disclose: 10.92% for the December 2025 stub, then 10.5%, 10.4% and 10.5% through September 2026. For the fourth quarter of 2026 the model uses the 10.82% that HPS Corporate Capital Solutions Fund reports for the loan, where the company disclosed 10.5% at September 30. From January 2027 the base rate is the three-month SOFR forward, 4.32% for the first quarter of 2027, peaking at 4.69% late in 2027 and easing to 4.45% by the end of 2030. The floor never binds. The answer notes that the curve “is not CME Term SOFR”.
The take-out is set on December 8, 2028, the third anniversary, when the prepayment premium has fallen to zero. The yield to take-out is higher than the yield to maturity because the OID and fees, 1.20% a year spread over three years, are earned faster. The SOFR forward curve page covers the curve behind these resets.
| B | C | D | E | F | G | H | I | J | L | |
|---|---|---|---|---|---|---|---|---|---|---|
| 56 | Holder | As of | Spread | Rate | Par ($000) | Cost ($000) | Fair value ($000) | Cost % par | FV % par | Yield at mark |
| 57 | Fortress Private Lending Fund (first lien term loan) | 9/30/2026 | 6.75% | 10.80% | 43,104 | 42,550 | 41,845 | 98.7% | 97.1% | 12.95% |
| 58 | HPS Corporate Capital Solutions Fund (first lien term loan) | 9/30/2026 | 6.75% | 10.82% | 11,842 | 11,694 | 11,446 | 98.8% | 96.7% | 13.11% |
Both funds list the loan at SOFR + 6.75%, the model’s margin. Fortress Private Lending Fund holds $43.1 million of par at a cost of 98.7% and a fair value of 97.1%, and HPS Corporate Capital Solutions Fund holds $11.8 million at 98.8% and 96.7%. Both fair values sit below cost, by 1.66% and 2.12% of cost. At those marks, the cash flows to maturity yield 12.95% and 13.11%. The BDC portfolio analysis page reads schedules like these across a portfolio.
What the public filings cannot tell you
The filings give the terms, the reported numbers and the guidance. The inputs that decide this underwriting, covenant EBITDA as the borrower calculates it, the litigation still to come and the 2027 plan, come only from management. Compound’s answer ends with the list, addressed to the sponsor and management.
- Compliance certificates for Q1 to Q3 2026 with the covenant EBITDA bridge. Run-rate addbacks of up to 25% are allowed, so in the answer’s words “their figure may be higher than the 5.69x I calculate.”
- A schedule of each litigation matter: amounts paid and accrued, insurance and remaining exposure. About $3.4 million of settlement payments are expected in the fourth quarter of 2026. This replaces the 50% credit.
- The 2027 budget and projections by brand: openings, closures, same store sales and how much deferred franchise revenue is left to recognize. These replace Compound’s growth and margin assumptions after 2026.
- A dated plan for the cost review, a 13-week cash flow forecast, and how restricted cash is used.
- A plan for the March 2028 step-down: an equity cure commitment, an amendment or a refinancing, and how the current strategic review could affect a take-out.
Our view
The model does the work a credit committee needs: it finds the binding constraint, and the constraint is the March 2028 step-down to 5.00x. Whether the loan clears it depends far more on 2027 and 2028 EBITDA growth than on the haircuts, which the covenant test does not use.
The litigation haircut is the right place to start an argument with management. It moves lender EBITDA by $13.6 million, and the company has added litigation back in every year on the sheet. Half credit is a defensible placeholder until a matter-by-matter schedule shows which settlements are finished. On the haircut basis, leverage of 7.9x is the figure to compare against the lender’s own sizing, and it is the reason the 6.0x flag trips from the first projected quarter.
The other side is that the management case misses the step-down by 1.2% of EBITDA on growth and margin that Compound set itself, and covenant EBITDA under the agreement can carry run-rate addbacks the model leaves out. A borrower with a cost review under way and 25% of run-rate capacity has room to report a covenant figure above the model’s. The two BDC marks, about two points below cost at September 30, 2026, are one date’s reading of the loan and sit beside the model, outside its cases.
Three things would change our view: compliance certificates that show the covenant EBITDA the borrower reports, a 2027 budget that sets growth and margins in place of the model’s, and a litigation schedule that shows how much of the $27.1 million recurs. From here the work moves to a credit memo on the loan and, in the downside, a recovery analysis of the first lien.
Xponential direct lending underwriting model (Excel)Compound’s workbook from this run: a Summary with the case results, covenant headroom and flags, an Assumptions sheet with a source or reason beside every input, Historicals with the lender view of each addback, quarterly Management, Lender and Downside cases, Loan Pricing with the BDC marks, and Sources.Download · FreeFAQ
How much addback credit should a direct lender give?
Full credit for non-cash items such as equity compensation and impairment, and partial or no credit for cash costs that recur, such as litigation, restructuring and executive turnover. In this model the haircuts take 24.8% off Xponential’s last-twelve-month Adjusted EBITDA, with a written reason beside each credit percentage.
What is the difference between a lender case and a management case?
The management case follows the company’s guidance and its own Adjusted EBITDA. The lender case lowers growth and margins and haircuts the addbacks the lender does not accept, and it is the case the loan is sized and flagged on. Here the two differ by $18.1 million of FY2027 EBITDA, $10.1 million from the operating assumptions and $8.0 million from the haircuts.
How do you calculate the all-in yield on a term loan with OID?
Take the lender’s cash flows: the funded amount net of OID and fees at close, quarterly interest at the floored base rate plus the margin, amortization, and repayment at par plus any premium at take-out or maturity, then solve for the internal rate of return. Funded at 96.41% of par, this loan yields 13.28% to a three-year take-out and 12.84% to maturity.
Should covenant headroom be measured on leverage or on EBITDA?
Measuring it as an EBITDA cushion, one minus actual leverage over the maximum, says how far EBITDA can fall before a breach, which is the question a lender is asking. On that basis Xponential’s headroom at September 30, 2026 is 18.7%, below the 20% the request set as a flag.
Does covenant EBITDA equal the company's Adjusted EBITDA?
Not necessarily. The credit agreement defines Consolidated EBITDA, and it can permit run-rate cost savings and other addbacks the public figure leaves out, here up to 25% of Consolidated EBITDA. This model uses the company’s Adjusted EBITDA as a proxy and asks for the compliance certificates to confirm it.





